Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome (COMPOSER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04023565
Recruitment Status : Recruiting
First Posted : July 17, 2019
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Sergey V. Nedogoda, Volgograd State Medical University

Brief Summary:

The aim of study is to assess the angioprotective effects of antihypertensive combination therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) > 10 m/s on the previously administered two-component combination antihypertensive therapy.

Open-label non-comparative prospective study for 24 week for each patient.


Condition or disease Intervention/treatment Phase
Arterial Hypertension Metabolic Syndrome Drug: perindopril + moxonidine Phase 4

Detailed Description:

According to European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension 2018 in case of previous combination at full dose does not allow to achieve the target Blood Pressure (BP), that therapy might be switch to different two-drug combination.

The study will enroll 120 hypertensive (Grade 1, 2 Arterial Hypertension (AH): Systolic Blood Pressure (SBP) 140-179 mm Hg and Diastolic Blood Pressure (DBP) 90-109 mm Hg According to ESC/ESH Guidelines 2018) patients with metabolic syndrome who met the inclusion criteria when treated with Angiotensin Converting Enzyme Inhibition(ACEi) /Angiotensin Receptor Blocker (ARB) + hydrochlorothiazide (HCTZ)/indapamide or +amlodipine (30 patients in each group):

  1. ACEi (except perindopril) + diuretic (HCTZ or indapamide)
  2. ACEi (except perindopril) + amlodipine
  3. ARB+ diuretic (HCTZ or indapamide)
  4. ARB+ amlodipine

Upon obtaining Inform Consent the previous therapy will be discontinued according to recommendations (gradually or at once).

After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.

If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).

FORBIDDEN TREATMENTS:

Any other antihypertensives (calcium antagonists, β-blockers, ACEi except perindopril, ARBs, diuretics) for routine AH management (except those used to resolve the uncontrolled hypertension).

CRITERIA FOR PREMATURE PATIENT WITHDRAWAL FROM THE STUDY:

  1. Withdrawal of informed consent by the patient at any time of the study.
  2. Need for uncontrolled hypertension management occurring more than 2 times weekly throughout the 2 consecutive weeks during study period.
  3. Need for the third antihypertensive drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome
Actual Study Start Date : March 11, 2019
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: perindopril + moxonidine
perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
Drug: perindopril + moxonidine

After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.

If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).

If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).





Primary Outcome Measures :
  1. Change in Pulse wave velocity (PWV) [ Time Frame: baseline and 24 weeks ]
    To assess the PWV after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.

  2. Change in Central Blood Pressure (BP) [ Time Frame: baseline and 24 weeks ]
    To assess the central BP changes (systolic BP, aortic pulse BP) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.

  3. Change in Reflected wave index [ Time Frame: baseline and 24 weeks ]
    To assess the reflected wave index after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.


Secondary Outcome Measures :
  1. Change in carbohydrate and lipid metabolism parameters markers [ Time Frame: baseline and 24 weeks ]
    To assess the homeostatic model assessment - insulin resistance (HOMA-IR), and lipid metabolism (total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL)) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.

  2. Change in the adipokine level [ Time Frame: baseline and 24 weeks ]
    To assess the adipokine level (leptin) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.

  3. Change in the Inflammatory marker level [ Time Frame: baseline and 24 weeks ]
    To assess the high sensible C-reactive Protein (hs-CRP) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level.

  4. Change in the renin-angiotensin-aldosterone system hyperactivation marker level [ Time Frame: baseline and 24 weeks ]
    To assess the renin-angiotensin-aldosterone system hyperactivation marker level (plasma aldosterone-to-renin ratio) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline level

  5. Change in the sympathoadrenal system hyperactivation marker levels [ Time Frame: baseline and 24 weeks ]
    To assess the sympathoadrenal system hyperactivation marker levels (urine excretion adrenaline, noradrenaline, dofamine levels) after 24 weeks of combination treatment with perindopril 10 mg and moxonidine 0.4-0.6 mg against baseline levels.

  6. Proportion of patients achieved target BP level [ Time Frame: Week 4, Week 12, Week 24 ]
    To assess the proportion of patients (%) achieving target BP levels <130/80 mm Hg at Week 4, Week 12, Week 24



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients (male and female) aging 18 to 70 years.
  2. Grade 1, 2 AH (SBP 140-179 mm Hg and/or DBP 90-109 mm Hg according 2018 ESH/ESC guidelines)
  3. PWV > 10 m/s
  4. Previous two-component antihypertensive therapy (ACEi/ARB+ diuretic (HCTZ or indapamide) or ACEI/ARB + amlodipine) during at least 6 months prior to the study enrollment
  5. Metabolic syndrome diagnosed by the 2009 Russian Society of Cardiology (RSC) National Guidelines criteria

    1. THE MAIN SIGN: central (abdominal) obesity defined as waist circumference (WC) above 80 cm in women and above 94 cm in men.
    2. ADDITIONAL CRITERIA:

    i. - arterial hypertension (BP ≥ 130/85 mm Hg) ii. - high triglycerides (≥ 1.7 mmol/l) iii. - decreased HDL-cholesterol (<1.0 mmol/l for men; <1.2 mmol/l for women) iv. - increased LDL-cholesterol > 3.0 mmol/l v. - fasting hyperglycaemia (fasting plasma glucose ≥ 6.1 mmol/l) vi. - impaired glucose tolerance (plasma glucose at 2 hours after glucose load from ≥7.8 to ≤11.1 mmol/l)

    Metabolic syndrome is defined as presence of central obesity and two of the additional criteria.

  6. Body Mass Index (BMI) >30 kg/m2.
  7. For female patients with childbearing potential: negative pregnancy test and willingness to use reliable methods of contraception until the study treatment completion
  8. Voluntarily signed informed consent to participate in the study.

Exclusion Criteria:

  1. Contraindications for using ACEi and imidazoline receptor agonists.
  2. Administration of perindopril or moxonidine during 6 months before the study onset.
  3. Metformin therapy for prophylaxis diabetes mellitus type 2 in patients with pre-diabetes, which had been started within 6 months before the study enrollment. (If a patient receives metformin for a long time, i.e., more than 6 months, he/she can be included in the study, and metformin discontinuation is not required).
  4. Statin and/or fibrate therapy started within 6 months before the study enrollment. (If a patient receives statins and/or fibrates for a long time, i.e., more than 6 months, he/she can be included in the study, and discontinuation of statins and fibrates is not required).
  5. Current diagnosis of unstable angina, acute and subacute myocardial infarction.
  6. Heart failure of any functional class.
  7. Grade 3 AH (≥ 180/110 mm Hg).
  8. Sinus bradycardia (heart rate ≤50/min).
  9. Type 1 or 2 diabetes mellitus.
  10. Severe comorbidities, including mental diseases.
  11. Acute conditions (infections, exacerbation of chronic diseases, injuries, surgical interventions).
  12. Alcohol abuse.
  13. Pregnancy and lactation.
  14. Serious renal dysfunction (Estimated Glomerular Filtration Rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) ≤30 ml/min/1.73 m2).
  15. Serious hepatic dysfunction
  16. Malignancies diagnosed and treated during the previous 5 years prior to study enrollment.
  17. Inability to understand the study and to give informed consent for participation in it.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04023565


Contacts
Layout table for location contacts
Contact: Sergey V. Nedogoda, Professor +79023643226 nedogodasv@rambler.ru

Locations
Layout table for location information
Russian Federation
Dept. of Therapy and Endocrinology Recruiting
Volgograd, Russian Federation, 400131
Contact: Sergey V. Nedogoda, Professor    +79023643226    nedogodasv@rambler.ru   
Sponsors and Collaborators
Sergey V. Nedogoda
Investigators
Layout table for investigator information
Principal Investigator: Sergey V. Nedogoda, Professor Volgograd State Medical University

Layout table for additonal information
Responsible Party: Sergey V. Nedogoda, Dr.Med.Sc., Professor, Volgograd State Medical University
ClinicalTrials.gov Identifier: NCT04023565     History of Changes
Other Study ID Numbers: MOXOD001
First Posted: July 17, 2019    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Sergey V. Nedogoda, Volgograd State Medical University:
perindopril
moxonidine

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Metabolic Syndrome
Syndrome
Disease
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Perindopril
Moxonidine
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents